Allan I Levey, Deqiang Qiu, Liping Zhao, William T Hu, Duc M Duong, Lenora Higginbotham, Eric B Dammer, Nicholas T Seyfried, Thomas S Wingo, Chadwick M Hales, Malú Gámez Tansey, David S Goldstein, Anees Abrol, Vince D Calhoun, Felicia C Goldstein, Ihab Hajjar, Anne M Fagan, Doug Galasko, Steven D Edland, John Hanfelt, James J Lah, David Weinshenker
The locus coeruleus is the initial site of Alzheimer's disease neuropathology, with hyperphosphorylated Tau appearing in early adulthood followed by neurodegeneration in dementia. Locus coeruleus dysfunction contributes to Alzheimer's pathobiology in experimental models, which can be rescued by increasing norepinephrine transmission. To test norepinephrine augmentation as a potential disease-modifying therapy, we performed a biomarker-driven phase II trial of atomoxetine, a clinically-approved norepinephrine transporter inhibitor, in subjects with mild cognitive impairment due to Alzheimer's disease...
June 30, 2022: Brain